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10Retinal Ganglion Cell Layer Change in Patients
Treated With Anti–Vascular Endothelial Growth
Factor for Neovascular Age-related Macular
DegenerationMARCO BECK, MARION R. MUNK, ANDREAS EBNETER, SEBASTIAN WOLF, AND MARTIN S. ZINKERNAGEL PURPOSE: To evaluate macular retinal ganglion cell
thickness in patients with neovascular age-related macu-
lar degeneration (AMD) and intravitreal anti–vascular
endothelial growth factor (VEGF) therapy.
 DESIGN: Retrospective case series with fellow-eye
comparison.
 METHODS: Patients with continuous unilateral anti-
VEGF treatment for subfoveal and juxtafoveal neovascu-
lar AMD and a minimum follow-up of 24 months were
included. The retinal nerve fiber (RNFL) and retinal gan-
glion cell layer (RGCL) in the macula were segmented us-
ing an ETDRS grid. RNFL and RGCL thickness of the
outer ring of the ETDRS grid were quantified at baseline
and after repeated anti-VEGF injections, and compared to
the patients’ untreated fellow eye. Furthermore, best-
corrected visual acuity (BCVA), age, and retinal pigment
epithelium (RPE) atrophy were recorded and correlated
with RNFL and RGCL.
 RESULTS: Sixty eight eyes of 34 patients (23 female and
11 male; mean age 76.7 (SD ± 8.2) with a mean number
of 31.5 (SD ± 9.8) anti-VEGF injections and a mean
follow-up period of 45.3 months (SD ± 10.5) were
included. Whereas the RGCL thickness decreased signif-
icantly compared to the noninjected fellow eye (P[ .01),
the decrease of the RNFL was not significant. Visual acu-
ity gain was significantly correlated with RGCL thickness
(r[ 0.52, P< .05) at follow-up and negatively corre-
lated (r [ L0.41, P < .05) with age. Presence of
RPE atrophy correlated negatively with the RGCL thick-
ness at follow-up (r[L0.37, P[ .03).
 CONCLUSION: During the course of long-term anti-
VEGF therapy there is a significant decrease of the
RGCL in patients with neovascular AMD compared to
the fellow (untreated) eye. (Am J Ophthalmol
2016;167:10–17.  2016 The Authors. Published byupplemental Material available at AJO.com.
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A
GE-RELATED MACULAR DEGENERATION (AMD) IS
one of the leading causes of visual impairment in
individuals over the age of 55 years in developed
countries.1 The neovascular form of AMD, with vascular
endothelial growth factor (VEGF) as one of the key factors,
causes severe and irreversible vision loss, frequently result-
ing in legal blindness.2,3 In recent years, VEGF inhibition
by anti-VEGF antibodies has significantly improved visual
outcomes in patients with neovascular AMD. However, in
many patients with neovascular AMD anti-VEGF needs to
be continuously administered over many years to persis-
tently suppress disease activity and maintain visual
function.
The need for long-term treatment with anti-VEGF
agents has also become evident in the extension studies,
where long-term outcomes 7-8 years after initiation of
intensive ranibizumab therapy suggest that many patients
require long-term treatment with anti-VEGF agents.4
However, despite the beneficial effect of anti-VEGF ther-
apy, long-term side effects are not clarified yet and are a
matter of ongoing controversy. There is evidence that
repeated long-term anti-VEGF treatment may accelerate
atrophy of different ocular tissues. Retinal pigment
epithelium atrophy,5 as well as scleral thinning, has
been reported.6 In the last years, several studies have
investigated the effect of intravitreal anti-VEGF injec-
tions on the peripapillary retinal nerve fiber layer
(RNFL). There exists some controversy regarding the ef-
fect of anti-VEGF agents on retinal ganglion cells
(RGCs). In mice, some reports suggest severe damage to
RGCs after local treatment with VEGF binding agents,7
while another report did not find any changes within
the retinal ganglion cell layer (RGCL) after VEGF recep-
tor blockade in mice.8 Because most studies have analyzed
peripapillary optical coherence tomography (OCT) scans,
these reports have focused on RNFL change after anti-
VEGF treatment. However, several studies focusing on
glaucoma patients have shown that RGCL thickness0002-9394
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changes may be a more sensitive marker for global and
regional visual field sensitivities.9,10
In the present study, we investigated RNFL and
RGCL changes in the macular area in eyes receiving
long-term intravitreal anti-VEGF treatment for neovas-
cular AMD using spectral-domain optical coherence to-
mography (Spectralis SDOCT; Heidelberg Engineering,
Heidelberg, Germany) and automated segmentation of
macular scans.FIGURE 1. Infrared images and retinal layer segmentation
with optical coherence tomography (OCT); co-localized
infrared image of a representative patient with average thick-
ness of the retinal nerve fiber layer (RNFL) in each quadrant
at baseline (Top), where C [ central ring and T [ temporal,
I [ inferior, N [ nasal, and S [ superior quadrants of the
inner (1) and outer (2) ring of the ETDRS grid. (Bottom)
Representative OCT image of inner retinal layers, where the
red, dashed line represents the internal limiting membrane,
the turquoise line represents the boundary between the
RNFL and the retinal ganglion cell layer (RGCL), and the pur-
ple, dotted line represents the boundary between RGCL and
inner plexiform layer.METHODS
THIS STUDY ISAN INSTITUTIONAL RETROSPECTIVE CASE SE-
ries with fellow-eye comparison and was conducted in
accordance with the Declaration of Helsinki and approved
by the local Ethics Committee (KEK-Nr. 093/13). Medical
records of the Department of Ophthalmology at the Uni-
versity Hospital Bern, Bern, Switzerland, were screened
for patients with exudative AMD under continuous anti-
VEGF treatment. The need for written consent from
each individual patient was waived because of the retro-
spective nature of the study. All data used in this study
were collected as part of the normal treatment protocol.
Study data were collected and managed using the REDCap
electronic data management tool hosted at our institution.
REDCap (Research Electronic Data Capture) is a secure,
web-based application designed to support data capture
for research studies.11 Patients were included in this retro-
spective study if they had unilateral exudative AMD and
had received at least 15 injections of bevacizumab (Avas-
tin; Genentech, South San Francisco, California, USA),
ranibizumab (Lucentis; Genentech, South San Francisco,
California, USA), and/or aflibercept (Eylea; Regeneron,
Tarrytown, New York, USA) with a minimum of
24 months of follow-up with the Spectralis OCT using
the rescan mode. Patients with bilateral exudative AMD
and previous therapy such as photodynamic therapy and
laser photocoagulation in the study or fellow eye were
excluded. Patients with signs of diabetic retinopathy or
glaucoma or a history of ocular hypertension were
excluded because this may have confounded the results
of retinal layer segmentation. Demographic data, best-
corrected visual acuity (BCVA), number of intravitreal in-
jections and administered anti-VEGF agents, duration of
treatment, and intraocular pressure (IOP) were recorded.
 IMAGE ACQUISITION AND EVALUATION: For OCT im-
aging a spectral-domain (SD)-OCT (Heidelberg Engineer-
ing, Dossenheim, Germany) was used. Images were
acquired using image alignment eye-tracking software
(TruTrack; Heidelberg Engineering) to obtain foveal volu-
metric retinal scans with 49 parallel B-scans consisting of
512 A-scans separated by 120 mm covering a volume of
203 20 degrees, whereby each B-scan was averaged 9 timesVOL. 167 RETINAL GANGLION CELLS DURI(automated real-time repetition rate ¼ 9).6 The baseline
was chosen to be the time point, when SD-OCT was intro-
duced in our clinic with the AutoRescan follow-up func-
tion available. For retinal layer segmentation the inbuilt
Heidelberg Eye Explorer version 1.9.10.0 (Heidelberg En-
gineering) was used to measure the RNFL and RGCL
thickness (Figure 1). Segmentation data were reviewed
by 2 experienced graders and adjusted manually if neces-
sary. The graders were not masked to which eye received
anti-VEGF therapy, because the neovascular component
was clearly evident in the OCT scans. Respective parame-
ters were evaluated at baseline and at last follow-up visit.
Heidelberg Eye Explorer segments 11 different retinal
boundaries: the inner limiting membrane (ILM); the
boundaries between the RNFL and the RGCL, between
the RGCL and the inner plexiform layer (IPL), between
the IPL and the inner nuclear layer (INL), between the
INL and the outer plexiform layer (OPL), and between
the OPL and the outer nuclear layer (ONL); the external
limiting membrane (ELM); 2 photoreceptor layers (PR1/
2); the retinal pigment epithelium (RPE); and the basal
membrane (BM) with the underlying choroid. Based on
this segmentation algorithm the area between the ILM11NG ANTI-VEGF TREATMENT
TABLE 1. Demographics and Clinical Characteristics of
Patient Cohort
Demographic Features
Study Eyes
(n ¼ 34)
Fellow Eyes
(n ¼ 34) Pa
Mean age 6 SD, y 76.7 6 8.2 76.7 6 8.2
Sex, F/M 23/11 23/11
Follow-up time,
mean 6 SD (mo)
45.3 6 10.5 44.1 6 11.3 .1012
Number of injections,
mean 6 SD
31.5 6 9.8 0 6 0.0 <.0001*
BCVA (ETDRS) at BL,
mean 6 SD
61.5 6 18.4 75.5 6 20.9 .0066*
BCVA (ETDRS) at FU,
mean 6 SD
57.9 6 20.2 67.9 6 21.9 .0517
IOP (mm Hg) at BL,
mean 6 SD
15.0 6 3.1 15.0 6 2.7 .9424
IOP (mm Hg) at FU,
mean 6 SD
14.8 63.0 SD 15.3 6 2.9 SD .1215
AREDS category 4 34 2
AREDS category 3 0 15
AREDS category 2 0 15
AREDS category 1 0 2
AREDS ¼ Age-Related Eye Disease Study; BCVA ¼ best-
corrected visual acuity; BL ¼ baseline; FU ¼ follow-up; IOP ¼
intraocular pressure.
AREDS categories: 4 ¼ presence of neovascular age-related
macular degeneration or geographic atrophy involving the cen-
tral subfield; 3 ¼ presence of large drusen (>125 mm) and/or
geographic atrophy outside the central foveal subfield; 2¼ inter-
mediate drusen (<125 mm) and/or retinal pigment epithelial ab-
normalities; 1 ¼ none or small drusen (<63 mm).
aSignificant difference (P< .05) in Student t test between study
eye and fellow eye. Asterisk indicates statistically significant dif-
ferences.
TABLE 2. Injections and Eye Characteristics
Study Eyes
(n ¼ 34)
Fellow Eyes
(n ¼ 34) Pa
Number of injections 31.6 6 9.8 SD 0 6 0.0 <.0001b,*
Number of injections at
study entry
13.4 6 10.2 0 6 0.0 <.0001b,*
Total number of
injections at FU
44.9 6 12.3 0 6 0.0 <.0001b,*
Duration from BL to
FU (mo)
45.3 6 10.5 44.1 6 11.3 .1012b
Total duration of
therapy (mo)
67.1 6 14.6 66.0 6 14.6 .1012b
Outer ring
RNFL thickness at
baseline (mm)
36.4 6 8.1 36.2 6 6.5 .9725c
RNFL thickness at
follow-up (mm)
32.2 6 6.4 36.8 6 6.9 .0438c,*
RGCL thickness at
baseline (mm)
29.6 6 6.6 32.9 6 5.4 .0681c
RGCL thickness at
follow-up (mm)
25.3 6 6.5 31.0 6 5.2 .0006c,*
BL ¼ baseline; FU ¼ follow-up; RGCL ¼ retinal ganglion cell
layer; RNFL ¼ retinal nerve fiber layer.
Data are mean 6 SD.
aAsterisk indicates statistically significant differences.
bStudent t test between study eye and fellow eye.
cOrdinary 1-way analysis of variance with Holm-Sidak multiple
comparisons.and the RNFL segmentation line (¼ mean RNFL thick-
ness) and the area between the RNFL and RGCL segmen-
tation line (¼ mean RGCL thickness) were automatically
calculated by the inbuilt software. Mean RNFL and RGCL
thickness of the outer ring (OR; r ¼ 3 mm) was calculated
using the implemented ETDRS grid. For further analyses
SDOCTs were graded for the presence and/or development
of RPE atrophy and the area of RPE atrophy measured in
the infrared image.
 STATISTICS: Statistical analyses were performed using
GraphPad Prism and R (GraphPad Prism 6; GraphPad
Software, LaJolla, California, USA; www.r-project.org).
In order to compare the segmentation data of the outer
ring between study and fellow eyes a 1-way analysis of
variance (ANOVA) with Holm-Sidak multiple compari-
sons test was employed. Differences between groups were
analyzed using an unpaired 2-tailed Student t test (Graph-
Pad Prism 6; GraphPad Software). Square root transfor-
mation was used to analyze RPE atrophy data.12 AMERICAN JOURNAL OFFurthermore, the association between BCVA, age, RPE
atrophy, and RNFL and RGCL decrease was investigated
by calculating pairwise correlations. Pearson or Spearman
correlation was used according to the D’Agostino & Pear-
son omnibus normality test. P values < .05 were consid-
ered statistically significant. Values are given in mean 6
standard deviation.RESULTS
THIS WAS A RETROSPECTIVE STUDY OF 34 PATIENTS (23
women) with a mean age of 76.7 6 8.2 years with fellow
eye comparison. Mean ETDRS BCVA of the study eyes
at baseline was 61.5 6 18.4 letters. Mean ETDRS BCVA
at the last follow-up visit was 57.9 6 20.2 letters. The
mean change in BCVA over the course of the study period
was 3.7 6 4.8 letters, which was not statistically signifi-
cant (P ¼ .45, t test). The mean number of anti-VEGF in-
jections was 31.56 9.8 (min.: 15; max.: 59 injections) and
the mean treatment period between baseline and follow-up
was 45.3 6 10.5 months (min.: 25.6; max.: 73.3 months).
IOP at baseline and at last follow-up visit as well as AREDSJULY 2016OPHTHALMOLOGY
FIGURE 2. Effect of continuous anti–vascular endothelial growth factor (VEGF) treatment on the retinal nerve fiber layer (RNFL)
and the retinal ganglion cell layer (RGCL). Box-and-whisker plots of RNFL thickness of the study eye and fellow eye at baseline (Top
left) and after treatment (end of study) with anti-VEGF for neovascular age-related macular degeneration (Top right). Box-and-
whisker plots of RGCL thickness at baseline (Bottom left) and after treatment with anti-VEGF for neovascular age-related macular
degeneration (Bottom right). ns[ not significant; *P< .05, ***P< .001; P values are adjusted for multiple comparisons.categories for the study and fellow eyes according to
AREDS report number 612 are summarized in Table 1.
The study eye received on average a mean number of
13.46 10.2 injections during a mean of 20.76 4.1 months
prior to the study baseline visit; thus a mean of 44.96 12.3
injections during a mean of 67.1 6 14.6 months were
administered overall (Table 2).
 RETINAL GANGLION CELL LAYER AND RETINAL NERVE
FIBER LAYER THICKNESS AT BASELINE: At baseline, the
RGCL thickness in the outer ring of the ETDRS grid was
slightly thinner in the study eye (29.66 6.6 mm) compared
with the fellow eyes (32.96 5.4mm); however, this was not
statistically significant (Figure 2, Bottom left). The RNFL
thickness did not show significant differences between
study and untreated fellow eyes at baseline (36.4 6
8.1 mm vs 36.2 6 6.5 mm) (Figure 2, Top left).
 RETINAL GANGLION CELL LAYER AND RETINAL NERVE
FIBER LAYER THICKNESS AT THE END OF THE STUDY: At
end of the study the RGCL was significantly thinner in the
study eye (256 6.5 mm) compared to untreated fellow eyes
(31.0 6 5.2 mm) (D 5.8 mm, P < .001, Holm-Sidak)
(Figure 2, Bottom right). The RNFL thickness in the
treated study eyes, at 32.2 6 6.4 mm, was significantlyVOL. 167 RETINAL GANGLION CELLS DURIthinner compared to the untreated fellow eyes, at 36.8 6
6.9 mm (D 4.6 mm, P ¼ .04, Holm-Sidak) (Figure 2,
Top right).
 CHANGE OF RETINAL GANGLION CELL LAYER AND
RETINAL NERVE FIBER LAYER DURING THERAPY WITH
ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR: In
the fellow eyes (controls) there were no significant longitu-
dinal changes in either the RNFL thickness or RGCL
thickness, which decreased by 0.7 mm (P ¼ .97, Holm-
Sidak) (Figure 3) and 1.4 mm (P ¼ .34, Holm-Sidak),
respectively (Figure 4). In the study eyes, RGCL thickness
showed a significant decrease between baseline and last
follow-up in the outer ETDRS ring (RGCL: D 4.4 6
0.9mm [SE of diff.], P¼ .01) (Figure 4), whereas the change
in RNFL did not reach statistical significance (RNFL:
D 4.2 6 1.5 mm [standard error of difference], P ¼ .07)
(Figure 3). CORRELATION OF AGE, VISUAL ACUITY MEASURE-
MENTS, INJECTIONS,ANDRETINALPIGMENTEPITHELIUM
ATROPHY: Visual acuity gain and RGCL thickness at the
last follow-up were positively correlated (P ¼ .01, r ¼
0.44) (Figure 5). There were weak but not significant
correlations between visual gain and decrease of RNFL13NG ANTI-VEGF TREATMENT
FIGURE 4. Representative map of retinal ganglion cell layer
(RGCL) thickness within the ETDRS grid at baseline (Top
left) and after treatment with anti–vascular endothelial
growth factor for neovascular age-related macular degenera-
tion (Top right). Graph showing mean RNFL thickness
within the outer ring of the ETDRS grid at baseline and
for the study eye (SE) and the fellow eye (FE). ns[ not sig-
nificant; *P < .05; P values are adjusted for multiple
comparisons.
FIGURE 3. Representative map of retinal nerve fiber layer
(RNFL) thickness within the ETDRS grid at baseline (Top
left) and after treatment with anti–vascular endothelial growth
factor (VEGF) for neovascular age-related macular degenera-
tion (Top right). Graph showing mean RNFL thickness within
the outer ring of the ETDRS grid at baseline and after treat-
ment with anti-VEGF for neovascular age-related macular
degeneration for the study eye (SE) and the fellow eye (FE).
ns [ not significant; P values are adjusted for multiple com-
parisons.(P ¼ .33, r ¼ 0.17) and RGCL thickness decrease (P ¼
.11, r ¼ 0.28), and between the number of injections
and the decrease of both the RNFL thickness (P ¼ .22,
r ¼ 0.22) and the RGLC thickness (P ¼ .34, r ¼ 0.17).
The age of the patients correlated negatively with the vi-
sual gain and the RGCL thickness at follow-up (P ¼ .03,
r ¼ 0.4). As expected, the correlation between the
RNFL thickness and the RGCL thickness at follow-up (P
< .0001, r ¼ 0.72) was high. The number of injections
showed no significant correlation with the RNFL thickness
at follow-up (P ¼ .53, r ¼ 0.1) or with the RGCL thick-
ness (P ¼ .34, r ¼ 0.17). Area of macular atrophy corre-
lated negatively with the RGCL thickness at follow-up
(r ¼ 0.37, P ¼ .03).DISCUSSION
THIS STUDY REPORTS CHANGES IN THE RGCL AND RNFL OF
patients under a continuous and frequent anti-VEGF14 AMERICAN JOURNAL OFtreatment regimen for exudative AMD. We report
significant changes in the RGCL with a decrease of
around 15% after an average of 31.5 injections and a
follow-up period of 45 months compared to 6% in the
untreated fellow eye. This is, to our knowledge, the first
report investigating changes in the RGCL layer after
repeated injections with anti-VEGF.
Although this change may not be clinically significant
for patients at this stage, there may be functional changes
resulting from RGCL thinning over longer follow-up pe-
riods. In addition, it may be of clinical relevance for pa-
tients suffering from other diseases that impair the
RGCL, such as glaucoma, a common disease in this age
group.
There are ambiguous data about the effect of anti-VEGF
therapy on RNFL, with only 1 study reporting significant
decrease of RNFL after 1 year of anti-VEGF treatment.13
The longest follow-up in most of the published studies on
the association between RNFL changes and anti-VEGF
treatment is around 2 years (Table 3). Most of these studies
did not find a correlation of RNFL change with anti-VEGF
therapy, and this is in keeping with our data.14–18 However,JULY 2016OPHTHALMOLOGY
FIGURE 5. (Top) Graph showing the correlation between
retinal nerve fiber layer thickness change (DRNFL) and retinal
nerve fiber layer change (DRGCL) (Spearman correlation).
(Bottom) Correlation matrix with visual acuity gain (DVA),
age, and thickness of retinal ganglion cell layer (RGCL) after
treatment with anti–vascular endothelial growth factor. EOS
[ end of study.because these studies analyzed the peripapillary RNFL,
there are so far no data on changes of RGCL under
continuous anti-VEGF therapy. The RGCL accounts for
up to 35% of the retinal thickness of the posterior pole,
and therefore changes may be less prone to segmentation
errors and more pronounced than changes in RNFL.19 Us-
ing automated retinal layer segmentation of the outer ring
of the ETDRS grid, we were able to show that, although
there is no significant change in RNFL in patients receiving
long-term anti-VEGF treatment, there is significant
decrease of the RGCL under long-term anti-VEGF treat-
ment.
There are several possible mechanisms that may
explain our findings that merit further discussion. In
the first instance, it has been shown that the RGCL
thickness is affected by AMD. In a cross-sectional study
the RGCL thickness was significantly reduced in eyes
with recent-onset neovascular AMD compared to
healthy control eyes.20 This reduction could be due to
chronically reduced input from damaged photoreceptorsVOL. 167 RETINAL GANGLION CELLS DURIto the ganglion cells, causing apoptosis of the RGCL.
This may be reflected in our findings that the presence
of macular atrophy correlated positively with RGCL
thickness after intravitreal injections with anti-VEGF
agents. In our study we did not find a significant decrease
of either RNFL or RGCL thickness in eyes with neovas-
cular AMD compared to their fellow eyes with non-
neovascular AMD, which is in keeping with recent
reports.20 However, there was a significant decline of
RGCL compared to baseline in eyes being intensively
treated with anti-VEGF agents.
Secondly, it is well known that intravitreal injections
cause short-term pressure elevation in the eye, similar to
acute glaucoma.13,21,22 With IOP reported to rise over
40 mm Hg after intravitreal injection of 0.05 mL,23
RGCLs may be damaged by the pressure spikes, and
this may explain the significant change in RGCL thick-
ness after repeated injection. The effect of repeated IOP
fluctuations has been confirmed in a rabbit model, where
9 anti-VEGF injections at 14-day intervals induced
RNFL damage.24
Lastly, it has been shown that VEGF-A signaling via
VEGFR-2 inhibits caspase-3 activation and that VEGF-
A acts as a survival factor for RGCs.7,25 A recent report
has shown increased apoptosis of RGCs after anti-VEGF
treatment by TUNEL staining in diabetic rats.26 Further-
more, VEGF inhibitors such as bevacizumab have been
shown to block the protective effect of VEGF on RGCs
in an in vitro model of oxidative stress.27 As such,
repeated exposure to anti-VEGF agents may affect the
neurophysiologic role of VEGF and therefore may impair
RGC homeostasis.
Although we cannot exclude the possibility that the
RGCL decrease is attributable to the natural course of
the disease, the decrease of RGCL during intensive
anti-VEGF treatment with relative stability of the dis-
ease would suggest that our observed changes may be
at least partly explained by the anti-VEGF treatment.
This study has limitations owing to its retrospective na-
ture. Furthermore, the effect size of our observations is
relatively small and therefore is unlikely to be clinically
significant, and there was no dose-response effect. How-
ever, there was a weak correlation between the number
of injections and the decrease of RNFL and RGCL, and
as such this study may have been underpowered to
detect a significant correlation between intravitreal in-
jections and RGCL change. Furthermore, there may be
putative differences in susceptibility of RGCs to intravi-
treal injections.
To our knowledge, this report constitutes the first
study in the literature evaluating longitudinal changes
of RNFL and RGCL during repeated treatment with
anti-VEGF agents. Further studies should identify pa-
tients at risk for RGC damage, such as patients with a
history of glaucoma.15NG ANTI-VEGF TREATMENT
TABLE 3. Study Review
Author Number of Patients
RNFL BL (mm)
(Mean 6 SD)
RNFL FU (mm)
(Mean 6 SD) Pa Number of Injections (Mean 6 SD)
Duration (mo)
(Mean 6 SD)
Parlak et al (2014)14 22 101.4 6 14.2 99.9 6 14.5 .814 4.86 6 2.18 12 6 0.0
Demirel et al (2014)15 29 92.3 6 7.7 92.46 6 8.1 .379 13.88 6 3.81 38.9 6 15.5
Shin et al (2014)16 82 98.0 6 11.7 97.5 6 12.1 .577 5.69 6 2.7 21.3 6 4.1
Sobaci et al (2013)17 (Ranibizumab) 35 105.3 6 6.9 104.6 6 8.4 .57 6.3 6 1.9 13.6 6 2.1
Sobaci et al (2013)17 (Bevacizumab) 30 105.8 6 8.1 104.6 6 8.1 .42 5.1 6 1.3 14.05 6 2.6
Martinez et al (2012)13 49 105.7 6 12.2 100.2 6 11.0 <.001* 4.8 6 1.6 12 6 0.0
Horsley et al (2010)18 37 92.4 6 15.2 93.8 6 15.2 .68 16.0 6 5.5 27.0 6 9.7
BL ¼ baseline; FU ¼ follow-up; RNFL ¼ retinal nerve fiber layer.
aDifference in Student t test between study eye and fellow eye. Asterisk indicates statistically significant difference.FUNDING/SUPPORT: NO FUNDINGORGRANTSUPPORT. FINANCIAL DISCLOSURES: MARIONR.MUNK: CONSULTANT FEES FROM
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